UBS Maintains a 'Neutral' on Bristol-Myers Squibb Co. (BMY); Orencia Data May Lead To Market Share Gains

UBS maintains a 'Neutral' on Bristol-Myers Squibb Co. (NYSE: BMY) price target of $34.00.

Analyst, Marc Goodman, is a little more positive on the company/stock, saying that recent data on Orencia positions the company to gain market share.

(NOTE - ORENCIA (abatacept) is a prescription medicine that reduces signs and symptoms in adults with moderate to severe rheumatoid arthritis (RA), including those who have not been helped enough by other medicines for RA. ORENCIA may prevent further damage to your bones and joints and may help your ability to perform daily activities)

For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.

Shares of Bristol-Myers Squibb Co. closed at $34.04 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA grants accelerated approval to Bristol Myers Squibb's Zenbexus
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• Bristol Myers Squibb plans $2.3B manufacturing campus in Houston